To evaluate the efficacy of dinitrochlorobenzene (DNCB) in patients with early HIV infection
by monitoring immunologic parameters and serum HIV RNA. To facilitate the understanding of
possible alterations in the immunological status of the HIV+ patient cohort.
Patients must have:
- EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests.
For HIV+ patients:
- Patients must fail to meet the AIDS-defining criteria.
- CD4 lymphocyte count between 200 - 500 cells/mm3.
Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites.
- Patients who are likely to commence antiretrovirals within the 6-month study period.
- Patients using other immunomodulator therapies or other alternative therapies.
- Patients likely to require chemotherapy during the course of the study.
- Patients who are likely to require significant UV light exposure during the study
- Patients who are likely to require radiation therapy during the course of the study.
- Prior exposure to DNCB.
- Patients who have used antiretroviral medications within the previous 3 months.